Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 149

Similar articles for PubMed (Select 22313330)

1.

The cost to managed care of managing pulmonary hypertension.

Said Q, Martin BC, Joish VN, Kreilick C, Mathai SC.

J Med Econ. 2012;15(3):500-8. doi: 10.3111/13696998.2012.665109. Epub 2012 Feb 22.

PMID:
22313330
2.

Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.

Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Appl Health Econ Health Policy. 2011 Nov 1;9(6):377-87. doi: 10.2165/11592440-000000000-00000.

PMID:
21888449
3.

Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.

Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Appl Health Econ Health Policy. 2011 Sep 1;9(5):293-303. doi: 10.2165/11592430-000000000-00000.

PMID:
21875160
4.

Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.

Angalakuditi M, Edgell E, Beardsworth A, Buysman E, Bancroft T.

J Med Econ. 2010;13(3):393-402. doi: 10.3111/13696998.2010.496694.

PMID:
20608882
5.

Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.

Copher R, Cerulli A, Watkins A, Laura Monsalvo M.

J Med Econ. 2012;15(5):947-55. doi: 10.3111/13696998.2012.690801. Epub 2012 May 22.

PMID:
22554140
6.

Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.

Doshi JA, Cai Q, Buono JL, Spalding WM, Sarocco P, Tan H, Stephenson JJ, Carson RT.

J Manag Care Spec Pharm. 2014 Apr;20(4):382-90.

7.
8.

Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States.

Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Curr Med Res Opin. 2011 Sep;27(9):1763-8. doi: 10.1185/03007995.2011.604310. Epub 2011 Jul 27.

PMID:
21793646
9.

Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.

Laliberté F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.

J Manag Care Pharm. 2009 May;15(4):312-22.

10.

Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population.

Furst DE, Clarke A, Fernandes AW, Bancroft T, Gajria K, Greth W, Iorga SR.

Lupus. 2013 Mar;22(3):268-78. doi: 10.1177/0961203312474087. Epub 2013 Jan 22.

PMID:
23340996
11.

All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.

Asche CV, Singer ME, Jhaveri M, Chung H, Miller A.

J Manag Care Pharm. 2010 Nov-Dec;16(9):703-12.

12.

Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection.

Tencer T, Friedman HS, Li-McLeod J, Johnson K.

J Manag Care Pharm. 2007 Nov-Dec;13(9):790-8.

13.

Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.

Oglesby A, Korves C, Laliberté F, Dennis G, Rao S, Suthoff ED, Wei R, Duh MS.

Appl Health Econ Health Policy. 2014 Apr;12(2):179-90. doi: 10.1007/s40258-014-0085-x.

PMID:
24573911
14.

Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study.

Berger A, Edelsberg J, Teal S, Mychaskiw MA, Oster G.

BMC Pulm Med. 2012 Dec 11;12:75. doi: 10.1186/1471-2466-12-75.

15.

Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients.

Bickston SJ, Waters HC, Dabbous O, Tang BI, Rahman M.

J Manag Care Pharm. 2008 May;14(4):352-62.

16.

Actuarial analysis of private payer administrative claims data for women with endometriosis.

Mirkin D, Murphy-Barron C, Iwasaki K.

J Manag Care Pharm. 2007 Apr;13(3):262-72.

17.

Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.

White RR, Lenhart G, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, Segraves AW.

Pharmacoeconomics. 2009;27(9):781-92. doi: 10.2165/11317560-000000000-00000.

PMID:
19757871
18.

Healthcare utilization and costs of patients with rosacea in an insured population.

Romanowicz M, Stephenson JJ, Del Rosso JQ, Lenhart G.

J Drugs Dermatol. 2008 Jan;7(1):41-9.

PMID:
18246697
19.

The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.

Asche CV, Joish VN, Camacho F, Drake CL.

Curr Med Res Opin. 2010 Aug;26(8):1843-53. doi: 10.1185/03007995.2010.488037.

PMID:
20515321
20.

Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.

Pelletier EM, Shim B, Goodman S, Amonkar MM.

Breast Cancer Res Treat. 2008 Mar;108(2):297-305. Epub 2007 Jun 19.

PMID:
17577662
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk